Editorial: Neuroendocrine tumors: the road to precision medicine.
作者信息
La Salvia Anna, Giuffrida Dario, Modica Roberta
机构信息
National Center for Drug Research and Evaluation, National Institute of Health (ISS), Rome, Italy.
Department of Oncology, Istituto Oncologico del Mediterraneo, Viagrande, Catania, Italy.
出版信息
Front Endocrinol (Lausanne). 2023 Jul 26;14:1253319. doi: 10.3389/fendo.2023.1253319. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Neuroendocrine tumors: the road to precision medicine.社论：神经内分泌肿瘤：精准医学之路
Front Endocrinol (Lausanne). 2023 Jul 26;14:1253319. doi: 10.3389/fendo.2023.1253319. eCollection 2023.
2
Clinical implications of lung neuroendocrine neoplasm classification.肺神经内分泌肿瘤分类的临床意义。
Expert Rev Anticancer Ther. 2021 Apr;21(4):377-387. doi: 10.1080/14737140.2021.1862654. Epub 2020 Dec 24.
3
Metastatic Neuroendocrine Tumors to Parotid Gland: Where Do They Come From?转移至腮腺的神经内分泌肿瘤：它们源自何处？
Int J Surg Pathol. 2023 Apr;31(2):167-174. doi: 10.1177/10668969221095267. Epub 2022 Apr 24.
4
Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data.神经内分泌肿瘤精准医学的分子谱分析和靶向作用：真实世界数据。
Eur J Cancer. 2023 Jun;186:122-132. doi: 10.1016/j.ejca.2023.03.024. Epub 2023 Mar 24.
5
Insulinoma-associated 1: A sensitive marker of neuroendocrine differentiation in cutaneous and metastatic neuroendocrine tumors.胰岛素瘤相关蛋白1：皮肤和转移性神经内分泌肿瘤中神经内分泌分化的敏感标志物。
J Cutan Pathol. 2021 Jan;48(1):8-10. doi: 10.1111/cup.13902. Epub 2020 Nov 18.
6
Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms.北欧 2023 年肺神经内分泌肿瘤诊治指南。
Acta Oncol. 2023 May;62(5):431-437. doi: 10.1080/0284186X.2023.2212411. Epub 2023 May 16.
7
Neuroendocrine neoplasms in the breast oncology field: dilemmas of nature and morphology.乳腺肿瘤领域的神经内分泌肿瘤：性质与形态学的困境
Front Endocrinol (Lausanne). 2023 Nov 1;14:1216424. doi: 10.3389/fendo.2023.1216424. eCollection 2023.
8
A new immunohistochemical marker, insulinoma-associated protein 1 (INSM1), for Merkel cell carcinoma: Evaluation of 24 cases.一种新的用于 Merkel 细胞癌的免疫组化标志物：胰岛素瘤相关蛋白 1（INSM1）的评估。
Ann Diagn Pathol. 2019 Jun;40:53-58. doi: 10.1016/j.anndiagpath.2019.04.002. Epub 2019 Apr 11.
9
177Lu-DOTATATE versus 177Lu-EDTMP versus cocktail/sequential therapy in bone-confined painful metastatic disease in medullary carcinoma of the thyroid and neuroendocrine tumour: can semiquantitative comparison of 68Ga-DOTATATE and 18F-fluoride PET-CT aid in personalized treatment decision making in selecting the best therapeutic option?177镥-奥曲肽与177镥-乙二胺四甲基膦酸对甲状腺髓样癌和神经内分泌肿瘤骨局限性疼痛性转移性疾病的疗效比较及联合/序贯治疗：68镥-奥曲肽和18F-氟化物PET-CT的半定量比较能否有助于在选择最佳治疗方案时做出个性化治疗决策？
Nucl Med Commun. 2016 Jan;37(1):100-2. doi: 10.1097/MNM.0000000000000397.
10
[Expression of CD200 and INSM1 in gastrointestinal and pancreatic neuroendocrine neoplasms and its diagnostic values].[CD200和INSM1在胃肠道及胰腺神经内分泌肿瘤中的表达及其诊断价值]
Zhonghua Bing Li Xue Za Zhi. 2021 Oct 8;50(10):1134-1138. doi: 10.3760/cma.j.cn112151-20210209-00144.
引用本文的文献
1
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons.血脂异常、降脂药物与神经内分泌肿瘤：新的前景。
Endocrine. 2024 Aug;85(2):520-531. doi: 10.1007/s12020-024-03767-7. Epub 2024 Mar 20.
本文引用的文献
1
Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists.奥曲肽和兰瑞肽靶向神经内分泌肿瘤：NET 专家的临床实践要点。
Cancer Treat Rev. 2023 Jun;117:102560. doi: 10.1016/j.ctrv.2023.102560. Epub 2023 Apr 17.
2
Lipid Metabolism and Homeostasis in Patients with Neuroendocrine Neoplasms: From Risk Factor to Potential Therapeutic Target.神经内分泌肿瘤患者的脂质代谢与稳态：从危险因素到潜在治疗靶点
Metabolites. 2022 Nov 2;12(11):1057. doi: 10.3390/metabo12111057.
3
Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?神经内分泌肿瘤的免疫治疗：嵌合抗原受体T细胞有何作用？
Cancers (Basel). 2022 Aug 18;14(16):3991. doi: 10.3390/cancers14163991.
4
Health-related quality of life in patients with neuroendocrine neoplasms: a two-wave longitudinal study.神经内分泌肿瘤患者的健康相关生活质量：一项两波纵向研究。
J Endocrinol Invest. 2022 Nov;45(11):2193-2200. doi: 10.1007/s40618-022-01872-w. Epub 2022 Jul 22.
5
Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives.神经内分泌肿瘤患者的治疗策略：当前观点。
Expert Rev Endocrinol Metab. 2022 Sep;17(5):389-403. doi: 10.1080/17446651.2022.2099840. Epub 2022 Jul 13.
6
Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis.通过多组学分析鉴定神经内分泌肿瘤中的功能途径和分子特征。
J Transl Med. 2022 Jul 6;20(1):306. doi: 10.1186/s12967-022-03511-7.
7
Prognostic significance of laterality in lung neuroendocrine tumors.肺神经内分泌肿瘤中侧别分布的预后意义。
Endocrine. 2022 Jun;76(3):733-746. doi: 10.1007/s12020-022-03015-w. Epub 2022 Mar 18.
8
Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.胃肠胰神经内分泌肿瘤（GEP-NENs）的危险因素：一项三中心病例对照研究。
J Endocrinol Invest. 2022 Apr;45(4):849-857. doi: 10.1007/s40618-021-01715-0. Epub 2022 Jan 18.
9
Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead.神经内分泌肿瘤的临床表观遗传学：前路漫漫。
Front Endocrinol (Lausanne). 2020 Dec 15;11:604341. doi: 10.3389/fendo.2020.604341. eCollection 2020.
10
Quality of Life in Patients with Neuroendocrine Neoplasms: The Role of Severity, Clinical Heterogeneity, and Resilience.神经内分泌肿瘤患者的生活质量：严重程度、临床异质性和韧性的作用。
J Clin Endocrinol Metab. 2021 Jan 1;106(1):e316-e327. doi: 10.1210/clinem/dgaa760.
Zotero 插件